ERS 2025: Benefits of synthetic control arms reinforced with buloxibutid’s results
On 29 September 2025, at the European Respiratory Society (ERS) Conference held in Amsterdam, the Netherlands, Vicore Pharma presented results…
Immunology
-
-
Roche bids to broaden MS pipeline and strengthen Ocrevus influence
Roche plans to present data at a major multiple sclerosis (MS) conference indicating the continued efficacy of its investigational Bruton…
-
aTyr Pharma stock crashes on Phase III pulmonary sarcoidosis fail
aTyr Pharma shares plunged more than 80% after its Phase III trial in pulmonary sarcoidosis failed to meet its primary…
-
Idiopathic pulmonary fibrosis breakthroughs may lead to first drug approval in years
Idiopathic pulmonary fibrosis (IPF) remains one of the most challenging lung diseases to treat, with progressive scarring, limited treatment options…
-
Novartis’ mAb could become first Sjögren’s disease drug after Phase III success
Novartis is hoping to gain approval for its Sjögren’s disease drug after it met the endpoints in two Phase III…
-
gMG race hots up as AstraZeneca’s star candidate meets Phase III targets
AstraZeneca has secured a win for its rare disease pipeline, with its Phase III trial of gefurulimab demonstrating the drug’s…
-
Merck KGaA’s lupus drug to advance to Phase III despite mixed data
Merck KGaA (Merck)’s investigational lupus therapy enpatoran will be advancing to Phase III trials after meeting the primary endpoint in…
-
Sanofi axes development of oral TNF inhibitor as monotherapy following Phase II fail
Sanofi will halt the development of its oral tumour necrosis factor (TNF) inhibitor balinatunfib as a monotherapy after it failed…
-
Vertex halts development of diabetes cell therapy after trial failure
Vertex Pharmaceuticals has discontinued the development of VX-264, a type 1 diabetes (T1D) cell therapy delivered via an implantable device,…
-
J&J and Protagonist’s icotrokinra scores in Phase IIb UC study
Johnson & Johnson (J&J) and Protagonist Therapeutics’s joint interleukin-23 (IL-23) inhibitor, icotrokinra, has met the primary endpoint in a Phase…
